张煜坤++++++戈伟

    [摘要] 肺癌是最致命的恶性肿瘤之一，高居全球肿瘤相关死亡的首位。随着多学科综合治疗的发展，肺癌患者的死亡率仍居高不下。KRAS基因突变是非小细胞肺癌最常见的突变类型。目前对KRAS基因突变的靶向治疗主要通过直接抑制KRAS基因、改变KRAS膜定位、抑制KRAS下游效应分子及抑制KRAS突变协同致死基因等方面进行研究。本文对KRAS基因突变的非小细胞肺癌靶向治疗的现况和进展进行综述。

    [关键词] 非小细胞肺癌；KRAS基因突变；抑制KRAS下游效应分子；靶向治疗

    [中图分类号] R734.2 [文献标识码] A [文章编号] 1673-7210(2017)06(a)-0032-04

    Progress in targeted therapy of KRAS mutations in non-small cell lung cancer

    ZHANG Yukun GE Wei▲

    The Two Department of Oncology， Renmin Hospital of Wuhan University， Hubei Province， Wuhan 430060， China

    [Abstract] Lung cancer is one of the most deadly malignancies， ranking the first in global cancer-related death. With the development of multidisciplinary comprehensive treatment， the mortality rate of patients with lung cancer is still high. KRAS gene mutations are the most common type of mutations in non-small cell lung. At present， the targeted therapy of KRAS gene mutation mainly through the direct inhibition of KRAS gene， change the KRAS membrane localization， inhibition of KRAS downstream effector molecules， inhibition of KRAS mutant synergistic lethal genes and other aspects of research. In this review ......